Status:
COMPLETED
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Lead Sponsor:
Eisai Inc.
Collaborating Sponsors:
Pfizer
Conditions:
Alzheimer's Disease
Dementia
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, ac...
Eligibility Criteria
Inclusion
- Clinically diagnosed Alzheimer's Disease with MMSE score 1\~12
- Have not been treated by any medication for Alzheimer's Disease in past 3 months
- Live in community or Assisted Living Facility
- Healthy or with chronic diseases that are medically controlled or stabilized
- Able to swallow tablets
Exclusion
- Any primary neurological or psychiatric diagnosis (including depressive disorder) other than Alzheimer's Disease
- Dementia caused by organic diseases other than Alzheimer's Disease
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
229 Patients enrolled
Trial Details
Trial ID
NCT00096473
Start Date
January 1 2001
End Date
September 1 2005
Last Update
April 1 2011
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Northport, Alabama, United States
2
Phoenix, Arizona, United States
3
Sun City, Arizona, United States
4
Tucson, Arizona, United States